<DOC>
	<DOCNO>NCT00619996</DOCNO>
	<brief_summary>The purpose study use Sorafenib plus Docetaxel evaluate pharmacodynamics ( PD ) Patients prostate cancer .</brief_summary>
	<brief_title>Study Sorafenib Docetaxel Metastatic Prostate Cancer</brief_title>
	<detailed_description>Background Prostate cancer common malignancy men second lead cause cancer death among male Western World . When tumor become refractory androgen withdrawal therapy , chemotherapy represent palliative treatment improvement quality life , particularly combination mitoxantrone prednisone . This observation lead numerous study evaluate potential use new chemotherapeutic agent Docetaxel patient metastatic androgen independent prostate cancer . Recently Docetaxel base regimen show improvement survival compare mitoxantrone phase III trial . However prognosis patient remain poor new effective tolerate approach need improve result chemotherapy . Rationale In recent study Raf kinase inhibitor protein ( RKIP ) encode suppressor gene find responsible metastatic process ; fact decrease RKIP expression associate increase invasive capability prostate cancer cell , presumably though activation MEK ERK phosphorilation . Sorafenib , novel signal transduction inhibitor , prevents tumor cell proliferation angiogenesis block Raf/Mek/Erk pathway level Raf kinase tyrosine kinase receptor VEGFR-2 PDGFR . In phase I study combination docetaxel Sorafenib evaluate prostate tumor . The treatment well tolerate one partial response ( 4 % ) 12 stable disease ( 50 % ) report . According data design phase II study evaluate association Sorafenib Docetaxel metastatic prostate cancer Simon 's Optimal two-stage design phase II clinical trial apply calculate sample size minimizes expect number patient accrue . The sample size calculate follow assumption : alpha error =0.05 , beta error =0.20 ; PD ( clinically uninteresting true progressive disease rate ) P1 ( sufficiently promise true progressive disease rate ) set 60 % 80 % . 11 patient enrol first stage : progressive disease &lt; 7 accrual stop drug 's combination reject . In case &gt; = 7 progressive disease 32 patient accrued second stage . The treatment accept &gt; = 30 progressive disease 43 patient observe</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients metastatic hormone refractory prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Pisa</keyword>
	<keyword>Ricci</keyword>
</DOC>